GB0906159D0 - Drug combination for the treatment of proteostatic diseases - Google Patents
Drug combination for the treatment of proteostatic diseasesInfo
- Publication number
- GB0906159D0 GB0906159D0 GBGB0906159.9A GB0906159A GB0906159D0 GB 0906159 D0 GB0906159 D0 GB 0906159D0 GB 0906159 A GB0906159 A GB 0906159A GB 0906159 D0 GB0906159 D0 GB 0906159D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- drug combination
- proteostatic
- diseases
- proteostatic diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000890 drug combination Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0906159.9A GB0906159D0 (en) | 2009-04-09 | 2009-04-09 | Drug combination for the treatment of proteostatic diseases |
PCT/GB2010/000710 WO2010116141A2 (en) | 2009-04-09 | 2010-04-07 | Drug combination for the treatment of proteostatic diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0906159.9A GB0906159D0 (en) | 2009-04-09 | 2009-04-09 | Drug combination for the treatment of proteostatic diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
GB0906159D0 true GB0906159D0 (en) | 2009-05-20 |
Family
ID=40750361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0906159.9A Ceased GB0906159D0 (en) | 2009-04-09 | 2009-04-09 | Drug combination for the treatment of proteostatic diseases |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0906159D0 (en) |
WO (1) | WO2010116141A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2484371E (en) | 2008-06-26 | 2015-03-03 | Orphazyme Aps | Use of hsp70 as a regulator of enzymatic activity |
ES2753169T3 (en) | 2010-11-30 | 2020-04-07 | Orphazyme As | Procedures to increase intracellular activity of Hsp70 |
US9265815B2 (en) | 2011-04-29 | 2016-02-23 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers |
JP7028556B2 (en) | 2013-05-03 | 2022-03-02 | セレクタ バイオサイエンシーズ インコーポレーテッド | Delivery of immunosuppressive agents with antigens for specific pharmacodynamic efficacy and induction of immune tolerance |
MX2017002933A (en) | 2014-09-07 | 2017-05-30 | Selecta Biosciences Inc | Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses. |
BR112017004948A2 (en) | 2014-09-15 | 2017-12-05 | Orphazyme Aps | pharmaceutical formulation. |
EP3442530A1 (en) | 2016-04-13 | 2019-02-20 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
RU2750154C2 (en) | 2016-04-29 | 2021-06-22 | Орфазим А/С | Arimoclomol for treatment of glucocerebrosidase-associated disorders |
WO2018169811A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
CA3202568A1 (en) | 2020-11-19 | 2022-05-27 | Zevra Denmark A/S | Processes for preparing arimoclomol citrate and intermediates thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
US7964617B2 (en) * | 2005-06-08 | 2011-06-21 | Amicus Therapeutics, Inc. | Methods for treating parkinsons disease and parkinsonism |
MX2009000032A (en) * | 2006-06-23 | 2009-01-23 | Amicus Therapeutics Inc | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF beta-GLUCOCEREBROSIDASE. |
WO2008054947A2 (en) * | 2006-10-02 | 2008-05-08 | The Brigham And Women's Hospital, Inc. | Structure of acid beta-glucosidase and methods for identifying therapeutic agents |
US9056101B2 (en) * | 2007-04-26 | 2015-06-16 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
WO2009049422A1 (en) * | 2007-10-18 | 2009-04-23 | The Hospital For Sick Children | Compositions and methods for enhancing enzyme activity in gaucher, gm1 -gangliosidosis/morquio b disease. and parkinson's disease |
US20100317690A1 (en) * | 2007-11-21 | 2010-12-16 | Summit Corporation Plc | Treatment of protein folding disorders |
EP2323652A2 (en) * | 2008-08-06 | 2011-05-25 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
-
2009
- 2009-04-09 GB GBGB0906159.9A patent/GB0906159D0/en not_active Ceased
-
2010
- 2010-04-07 WO PCT/GB2010/000710 patent/WO2010116141A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2010116141A3 (en) | 2011-03-31 |
WO2010116141A2 (en) | 2010-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL259475A (en) | Combination therapy for the treatment of diabetes | |
HK1163500A1 (en) | Pharmaceutical composition for the treatment of heart diseases | |
IL219073A (en) | Pharmaceutical combination for treatment of cancer | |
EP2432476A4 (en) | Methods for treating or preventing ophthalmological diseases | |
GB0910003D0 (en) | Novel compounds for the treatment of neurodegenerative diseases | |
ZA200906210B (en) | 3-Imidazolyl-Indoles for the treatment of proliferative diseases | |
ZA201301601B (en) | Treatment of diseases | |
HK1215787A1 (en) | Pharmaceutical combination for the treatment of pain | |
ZA201202596B (en) | Compounds for the treatment of dyslipidemia and related diseases | |
EP2613786A4 (en) | Treatment of diseases | |
GB0906159D0 (en) | Drug combination for the treatment of proteostatic diseases | |
IL208357A0 (en) | Spiro-indole derivatives for the treatment of parasitic diseases | |
GB0908193D0 (en) | Treatment of disease state | |
HK1171677A1 (en) | Composition for the treatment of hemorrhoids and related diseases | |
ZA201302390B (en) | Arylosulfonamides for the treatment of cns diseases | |
GB0715790D0 (en) | Drug combination for the treatment of sialorrhoea | |
EP2599776A4 (en) | Therapeutic agent for neurological diseases | |
IL219050A0 (en) | Pharmaceutical composition for the treatment of bladder disorders | |
EP2500029A4 (en) | Therapeutic agent for gastrointestinal diseases | |
GB0901727D0 (en) | The treatment of ophthalmic diseases | |
GB0801511D0 (en) | The treatment of ophthalmic diseases | |
GB0908666D0 (en) | Treatment of proteostatic disease | |
GB0920651D0 (en) | Molecular methods for the treatment of disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |